Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
McKesson
Merck
Johnson and Johnson

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD0914

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug AZD0914?

AZD0914 is an investigational drug.

There have been 5 clinical trials for AZD0914. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2014.

The most common disease conditions in clinical trials are Gonorrhea and [disabled in preview]. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), Entasis Therapeutics, and AstraZeneca.

There are five US patents protecting this investigational drug and thirty-seven international patents.

Recent Clinical Trials for AZD0914
TitleSponsorPhase
Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female SubjectsNational Institute of Allergy and Infectious Diseases (NIAID)Phase 1
A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female VolunteersNational Institute of Allergy and Infectious Diseases (NIAID)Phase 1
AZD0914 Phase 1 ADME Study in Healthy VolunteersEntasis TherapeuticsPhase 1

See all AZD0914 clinical trials

Clinical Trial Summary for AZD0914

Top disease conditions for AZD0914
Top clinical trial sponsors for AZD0914

See all AZD0914 clinical trials

US Patents for AZD0914

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD0914   Start Trial Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections Entasis Therapeutics Limited (London, GB)   Start Trial
AZD0914   Start Trial Compounds and methods for treating bacterial infections AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD0914   Start Trial Compounds and methods for treating bacterial infections Entasis Therapeutics Limited (London, GB)   Start Trial
AZD0914   Start Trial Compounds and methods for treating bacterial infections Entasis Therapeutics Limited (London, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD0914

Drugname Country Document Number Estimated Expiration Related US Patent
AZD0914 Australia 2015265620 2034-05-29   Start Trial
AZD0914 Canada 2948438 2034-05-29   Start Trial
AZD0914 China 106659725 2034-05-29   Start Trial
AZD0914 Eurasian Patent Organization 201692250 2034-05-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Boehringer Ingelheim
Express Scripts
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.